Patents by Inventor Bryan Laffitte

Bryan Laffitte has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • TREATMENT COMPRISING FXR AGONISTS
    Publication number: 20220347190
    Abstract: The invention provides, FXR agonists for the treatment of a condition mediated by Farnesoid X receptor (FXR), in particular liver disease or intestinal disease, in a subject in need thereof, to reduce drug-induced adverse side effects inpatients suffering from such diseases or conditions.
    Type: Application
    Filed: September 18, 2020
    Publication date: November 3, 2022
    Inventors: Michael Badman, Clifford Brass, Bryan Laffitte, Iwona KSIAZEK
  • METHODS FOR TREATING LIVER DISORDERS USING FXR AGONISTS
    Publication number: 20220313677
    Abstract: The invention provides methods for modulating the activity of farnesoid X receptors (FXRs) using specific FXR agonists, in particular for treating or preventing liver diseases.
    Type: Application
    Filed: April 26, 2022
    Publication date: October 6, 2022
    Inventors: Michael BADMAN, Jin CHEN, Bryan LAFFITTE, Sam LINDGREN
  • Methods for treating liver disorders using FXR agonists
    Patent number: 11344540
    Abstract: The invention provides methods for modulating the activity of farnesoid X receptors (FXRs) using specific FXR agonists, in particular for treating or preventing liver diseases.
    Type: Grant
    Filed: February 20, 2017
    Date of Patent: May 31, 2022
    Assignee: Novartis AG
    Inventors: Bryan Laffitte, Michael Badman, Jin Chen, Sam Lindgren
  • Methods for treating gastrointestinal disorders using FXR agonists
    Patent number: 11229634
    Abstract: The invention provides methods for modulating the activity of farnesoid X receptors (FXRs) using specific FXR agonists, in particular for treating or preventing liver and gastrointestinal diseases.
    Type: Grant
    Filed: February 17, 2017
    Date of Patent: January 25, 2022
    Assignee: Novartis AG
    Inventors: Bryan Laffitte, Michael Badman, Jin Chen, Sam Lindgren
  • METHODS FOR TREATING LIVER DISORDERS USING FXR AGONISTS
    Publication number: 20210386729
    Abstract: The invention provides methods for modulating the activity of farnesoid X receptors (FXRs) using specific FXR agonists, in particular for treating or preventing liver diseases and disorders. In one embodiment, the invention provides a pharmaceutical unit dosage form composition, comprising a compound of Formula (I) or a stereoisomer, enantiomer or pharmaceutically acceptable salt thereof.
    Type: Application
    Filed: July 23, 2021
    Publication date: December 16, 2021
    Inventors: Michael BADMAN, Jin CHEN, Bryan LAFFITTE, Sam LINDGREN
  • FXR AGONISTS FOR THE TREATMENT OF LIVER DISEASES
    Publication number: 20210361638
    Abstract: The invention provides methods for treating or preventing a condition mediated by the farnesoid X receptor (FXR), comprising administering tropifexor, a pharmaceutically acceptable salt, an amino acid conjugate or an acyl glucuronide conjugate thereof, at a dose of about 140 ?g to about 250 ?g, to a subject in need thereof.
    Type: Application
    Filed: November 28, 2018
    Publication date: November 25, 2021
    Inventors: Michael Badman, Clifford Brass, Bryan Laffitte
  • COMBINATION OF FXR AGONISTS
    Publication number: 20210290610
    Abstract: The invention provides pharmaceutical compositions comprising a farnesoid X receptor (FXR) agonist and another therapeutic agent, in particular for treating or preventing liver diseases or disorders.
    Type: Application
    Filed: September 12, 2017
    Publication date: September 23, 2021
    Inventors: Andreas BAUER, Bryan LAFFITTE, Patrick MUELLER
  • NOVEL REGIMES OF FXR AGONISTS
    Publication number: 20210283105
    Abstract: The invention provides novel regimens of farnesoid X receptor (FXR) agonist and methods for modulating the activity of farnesoid X receptors (FXRs) using novel regimes of specific FXR agonists, in particular for treating or preventing fibrotic or cirrhotic diseases or disorders, such as liver diseases.
    Type: Application
    Filed: June 2, 2021
    Publication date: September 16, 2021
    Inventors: Michael BADMAN, Andreas BAUER, Jin CHEN, Bryan LAFFITTE, Patrick MUELLER, Rachel SOON
  • Methods for treating liver disorders using FXR agonists
    Patent number: 11110083
    Abstract: The invention provides methods for modulating the activity of farnesoid X receptors (FXRs) using specific FXR agonists, in particular for treating or preventing liver diseases and disorders.
    Type: Grant
    Filed: February 20, 2017
    Date of Patent: September 7, 2021
    Assignee: Novartis AG
    Inventors: Bryan Laffitte, Michael Badman, Jin Chen, Sam Lindgren
  • Regimes of FXR agonists
    Patent number: 11052069
    Abstract: The invention provides novel regimens of farnesoid X receptor (FXR) agonist and methods for modulating the activity of farnesoid X receptors (FXRs) using novel regimes of specific FXR agonists, in particular for treating or preventing fibrotic or cirrhotic diseases or disorders, such as liver diseases.
    Type: Grant
    Filed: September 12, 2017
    Date of Patent: July 6, 2021
    Assignee: Novartis AG
    Inventors: Bryan Laffitte, Andreas Bauer, Michael Badman, Jin Chen, Patrick Mueller, Rachel Soon
  • COMBINATIONS COMPRISING FXR AGONISTS
    Publication number: 20200276178
    Abstract: The invention provides pharmaceutical compositions comprising a farnesoid X receptor (FXR) agonist or caspase inhibitor and another therapeutic agent, e.g.. PPAR-delta agonist in particular for treating or preventing liver diseases or disorders.
    Type: Application
    Filed: September 11, 2018
    Publication date: September 3, 2020
    Inventors: Michael Badman, Clifford Brass, Bryan Laffitte
  • NOVEL REGIMES OF FXR AGONISTS
    Publication number: 20190262313
    Abstract: The invention provides novel regimens of farnesoid X receptor (FXR) agonist and methods for modulating the activity of farnesoid X receptors (FXRs) using novel regimes of specific FXR agonists, in particular for treating or preventing fibrotic or cirrhotic diseases or disorders, such as liver diseases.
    Type: Application
    Filed: September 12, 2017
    Publication date: August 29, 2019
    Inventors: Bryan LAFFITTE, Andreas BAUER, Michael BADMAN, Jin CHEN, Patrick MUELLER, Rachel SOON
  • METHODS FOR USING FXR AGONISTS
    Publication number: 20190161483
    Abstract: The invention provides methods for modulating the activity of farnesoid X receptors (FXRs) using specific doses of tropifexor, in particular for treating or preventing liver diseases.
    Type: Application
    Filed: November 28, 2018
    Publication date: May 30, 2019
    Inventors: Michael Badman, Clifford Brass, Bryan Laffitte
  • METHODS FOR USING FXR AGONISTS
    Publication number: 20190083481
    Abstract: The invention provides methods for modulating the activity of farnesoid X receptors (FXRs) using specific FXR agonists, in particular for treating or preventing liver diseases and disorders.
    Type: Application
    Filed: February 20, 2017
    Publication date: March 21, 2019
    Inventors: Bryan LAFFITTE, Michael BADMAN, Jin CHEN, Sam LINDGREN
  • AZABICYCLOOCTANE DERIVATIVES AS FXR AGONISTS FOR USE IN THE TREATMENT OF LIVER AND GASTROINTESTINAL DISEASES
    Publication number: 20190083473
    Abstract: The invention provides methods for modulating the activity of farnesoid X receptors (FXRs) using compounds of Formula (I) or (II). In particular, the invention provides for the use of compounds of Formula (I) or (II), or a stereoisomer, enantionmer or pharmaceutically acceptable salt thereof, for treating or preventing liver and gastrointestinal diseases.
    Type: Application
    Filed: September 20, 2018
    Publication date: March 21, 2019
    Inventors: Michael Badman, Lloyd B. Klickstein, Bryan Laffitte
  • COMBINATIONS COMPRISING FXR AGONISTS
    Publication number: 20190076500
    Abstract: The invention provides pharmaceutical compositions comprising a farnesoid X receptor (FXR) agonist or caspase inhibitor and another therapeutic agent, e.g. PPAR-delta agonist in particular for treating or preventing liver diseases or disorders.
    Type: Application
    Filed: September 11, 2018
    Publication date: March 14, 2019
    Inventors: Michael Badman, Clifford Brass, Bryan Laffitte
  • METHODS FOR USING FXR AGONISTS
    Publication number: 20190046518
    Abstract: The invention provides methods for modulating the activity of farnesoid X receptors (FXRs) using specific FXR agonists, in particular for treating or preventing liver and gastrointestinal diseases.
    Type: Application
    Filed: February 17, 2017
    Publication date: February 14, 2019
    Inventors: Bryan LAFFITTE, Michael BADMAN, Jin CHEN, Sam LINDGREN
  • METHODS FOR USING FXR AGONISTS
    Publication number: 20190046519
    Abstract: The invention provides methods for modulating the activity of farnesoid X receptors (FXRs) using specific FXR agonists, in particular for treating or preventing liver diseases.
    Type: Application
    Filed: February 20, 2017
    Publication date: February 14, 2019
    Inventors: Bryan LAFFITTE, Michael BADMAN, Jin CHEN, Sam LINDGREN
  • AZABICYCLOOCTANE DERIVATIVES AS FXR AGONISTS FOR USE IN THE TREATMENT OF LIVER AND GASTROINTESTINAL DISEASES
    Publication number: 20170368038
    Abstract: The invention provides methods for modulating the activity of farnesoid X receptors (FXRs) using compounds of Formula (I) or (II). In particular, the invention provides for the use of compounds of Formula (I) or (II), or a stereoisomer, enantionmer or pharmaceutically acceptable salt thereof, for treating or preventing liver and gastrointestinal diseases.
    Type: Application
    Filed: December 8, 2015
    Publication date: December 28, 2017
    Inventors: Michael Badman, LIoyd B. Klickstein, Bryan Laffitte
  • Novel use of liver X receptor agonists
    Publication number: 20050036992
    Abstract: This invention provides novel methods for modulating expression of glut4 and other genes involved in glucose metabolism, and methods for treating or ameliorating diabetes and related diseases. The methods comprise administering to cells in a subject an effective amount of an LXR agonist and thereby modulating expression of those genes that are important for glucose uptake or gluconeogenesis. The modulation will lead to increased uptake of glucose by cells in the subject and/or reduced glucose output in the liver, and accordingly ameliorate symptoms associated with, e.g., type II diabetes.
    Type: Application
    Filed: December 22, 2003
    Publication date: February 17, 2005
    Applicants: IRM LLC, The Regents of the University of California
    Inventors: Enrique Saez, Peter Tontonoz, Bryan Laffitte, Jing Li